Target intelligence / Profile preview

Melatonin receptor type 1A (MT1) (MT1)

Target
MT1
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

Melatonin receptor type 1A (MT1), encoded by the MTNR1A gene, is a high-affinity G protein-coupled receptor (GPCR) that plays a fundamental role in regulating circadian rhythms, sleep-wake cycles, and seasonal reproductive processes. It is primarily localized in the suprachiasmatic nucleus (SCN) of the hypothalamus, the master pacemaker of the mammalian circadian system, as well as the pituitary gland and retina. Upon activation by its endogenous ligand melatonin or synthetic agonists, MT1 couples to Gi/o proteins to inhibit adenylate cyclase activity, thereby decreasing intracellular cyclic AMP (cAMP) levels and suppressing neuronal firing in the SCN to promote sleep. Dysregulation of MT1 signaling is implicated in sleep disorders such as insomnia and non-24-hour sleep-wake disorder, as well as major depressive disorder and metabolic conditions like type 2 diabetes. Therapeutic targeting of MT1 with agonists like ramelteon, tasimelteon, and agomelatine is widely utilized to facilitate sleep onset, resynchronize circadian rhythms, and manage depressive symptoms.

Other names
Melatonin receptor 1AMel-1A-RMel1a receptorMTNR1AMTR-1A
02

Mechanism of action

Agonism of the G protein-coupled receptor, leading to Gi/o protein coupling, inhibition of adenylate cyclase, and reduction of intracellular cAMP levels.

03

Biological functions

Signal transductionCircadian rhythm regulationSleep regulationReproductive regulationVasoconstriction
04

Disease associations

InsomniaDepressionCircadian rhythm sleep disorderType 2 diabetesAlzheimer's disease
05

Safety considerations

SomnolenceDizzinessHeadacheHormonal changes (e.g., decreased testosterone, increased prolactin)Complex sleep behaviors (e.g., sleep-walking, sleep-driving)Hepatic impairment risks (contraindicated in severe hepatic impairment)Drug interactions (e.g., with strong CYP1A2 inhibitors like fluvoxamine)
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Dim light melatonin onset (DLMO)Polysomnography parametersCircadian phase markersMTNR1A genetic polymorphisms (e.g., rs2119882)

Beyond the preview

Go deeper on Melatonin receptor type 1A (MT1) (MT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melatonin receptor type 1A (MT1) (MT1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call